Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients-Reference-Cited by-同舟云学术

Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients

Published:2020-12-28 Issue:7 Volume:236 Page:5325-5338
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Tahmasebi Safa¹,El‐Esawi Mohamed A.²,Mahmoud Zaid Hameed³,Timoshin Anton⁴,Valizadeh Hamed⁵,Roshangar Leila⁶^ORCID,Varshoch Mojtaba⁷,Vaez Aydin⁷,Aslani Saeed⁸,Navashenaq Jamshid G.⁹^ORCID,Aghebati‐Maleki Leili¹⁰,Ahmadi Majid⁶^ORCID

Affiliation:

1. Department of Immunology, Healthy Faculty Tehran University of Medical Sciences Tehran Iran

2. Department of Botany, Faculty of Science Tanta University Tanta Egypt

3. Department of Chemistry, College of Science Diyala University Baquba Iraq

4. Department of Propaedeutics of Dental Diseases I. M. Sechenov First Moscow State Medical University (Sechenov University) Moscow Russia

5. Tuberculosis and Lung Disease Research Center Tabriz University of Medical Sciences Tabriz Iran

6. Stem Cell Research Center Tabriz University of Medical Sciences Tabriz Iran

7. Infectious and Tropical Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran

8. Department of Immunology, School of Medicine Tehran University of Medical Sciences Tehran Iran

9. Noncommunicable Diseases Research Center Bam University of Medical Sciences Bam Iran

10. Immunology Research Center Tabriz University of Medical Sciences Tabriz Iran

Funder

Tabriz University of Medical Sciences

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.30233

Reference50 articles.

1. Altered T‐cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities

2. Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment

3. Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial

4. Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: Non randomized, open-label clinical trial

5. The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RETRACTION: Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients;Journal of Cellular Physiology;2024-07-16

2. Curcumin as a regulator of Th17 cells: Unveiling the mechanisms;Food Chemistry: Molecular Sciences;2024-07

3. Nanoform of curcumin: expansion in therapeutic applications;Advances in Traditional Medicine;2024-05-25

4. Phase change materials in textiles: synthesis, properties, types and applications – a critical review;Textile Research Journal;2024-05-14

5. Nanocurcumin modulates Th17 cell responses in moderate and severe COPD patients;Heliyon;2024-05